InnoCare Pharma Limited reported no movement in its authorised, issued or treasury shares for October 2026, underscoring capital stability as the biopharmaceutical group progresses through multiple equity incentive schemes.

Authorised and Issued Capital • Authorised share capital closed the month unchanged at 25.00 billion ordinary shares with a par value of USD 0.000002 each, equal to USD 50,000.

• Hong Kong-listed ordinary shares (ticker: 09969) ended October with 1.49 billion shares in issue (excluding 2.49 million treasury shares), identical to September.

• A separate tranche of 273.40 million ordinary shares remains listed on the Shanghai Stock Exchange’s STAR Market; this figure likewise showed no monthly movement.

Treasury Shares • Treasury stock was stable at 2.49 million shares, with no repurchases, cancellations or transfers during the period.

Public Float • InnoCare confirmed compliance with the Hong Kong Main Board’s minimum 25% public float requirement as at 31 October 2026.

Equity Incentive Schemes – Capacity Unused in October Although no new shares were issued, the company retains sizeable headroom under three RMB-denominated restricted share incentive plans: 1. 2023 Scheme: Up to 2.45 million shares remain available. 2. 2024 Scheme: Up to 8.91 million shares remain available. 3. 2026 Scheme: Up to 8.00 million shares remain available. Cumulative lapses to date amount to 1.16 million shares across the 2023–2026 programmes.

Governance The monthly return was signed by Chairperson and Executive Director Dr. Jisong Cui and filed with Hong Kong Exchanges and Clearing on 5 November 2026.

Conclusion October’s filing highlights InnoCare Pharma’s unchanged share structure and adherence to listing requirements, while indicating latent dilution capacity through existing share incentive schemes that have yet to be exercised.